FAST TRACK EVALUATION PERIOD Sample Clauses

FAST TRACK EVALUATION PERIOD. Angiotech shall have twelve (12) months following receipt of the complete information and materials described in Section 6.2.1 to evaluate the Fast Track Compounds. Angiotech can request up to an additional six (6) months to evaluate any particular Fast Track Compound in addition to the 12-month period described in the preceding sentence, with CombinatoRx's consent to such request not to be unreasonably withheld (such 12-month period, together with any applicable 6-month period, the "FAST TRACK EVALUATION PERIOD"). At any time prior to the end of the applicable Fast Track Evaluation Period, Angiotech may designate one or more Fast Track Compounds as Selected Compounds by written notice to CombinatoRx of such designation. All Fast Track Compounds not selected by Angiotech are deemed rejected and Angiotech shall have no rights with respect to rejected Fast Track Compounds and shall promptly return to CombinatoRx all Information and materials related to such Fast Track Compounds that were provided to Angiotech by CombinatoRx (except one copy of which may be retained by Angiotech solely in its legal files for archival purposes to ensure its continuing compliance with this Agreement). [**] PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS EXHIBIT HAS BEEN FILED WITH THE COMMISSION.